Johnson&Johnson's long-acting schizophrenia therapy has been approved in China. Johnson&Johnson announced that its long-acting injection, Shanjiuda, which is administered every six months, has recently obtained market approval from the National Medical Products Administration for use in adult schizophrenia patients who have received sufficient treatment with palmatide injection (3M) for at least three months.